卵巢癌患者化疗前后淋巴细胞亚群分析

Analysis of lymphocyte sub-cluster in the patients with ovarian cancer around the chemotherapy

目的探讨化疗对卵巢癌患者免疫功能的影响。方法收集卵巢癌行化疗患者34例（卵巢癌组），以同期体检的健康妇女30例作为对照组。检测两组外周血淋巴细胞亚群CD^3＋、CD4^＋、CD8^＋、CD25^＋等指标，分析各淋巴细胞亚群情况。结果卵巢癌组患者外周血CD3^＋、CD4^＋以及CD4^＋／CD8^＋均较对照组显著降低（0．5524±0．1121比0．6685±0．0869、0．3183±0．0864比0．4139±0．0524、1．06±0．29比1．43±0．21），CD4^＋CD25^＋较对照组显著上升（0．1026±0．0418比0．0287±0．0132），差异有统计学意义（P〈0．05）。卵巢癌组患者外周血淋巴细胞亚群化疗后1周与化疗前比较差异无统计学意义（P〉0．05）；化疗后3周CD3^＋CD4^以及CD4^＋／CD25^＋均较化疗前显著升高，CD4^＋CD25^＋较化疗前显著下降，差异有统计学意义（P〈0．05）。结论卵巢癌患者体内淋巴细胞亚群比例失调，化疗可改善卵巢癌的免疫抑制状态，恢复正常的淋巴细胞亚群比例。

Objective To detect the effects of chemotherapy on the immune function of patients with ovarian cancer. Methods Thirty-four patients with ovarian cancer （ovarian cancer group） who accepted chemotherapy were collected. Thirty healthy women were used as control group. The lymphocyte sub-cluster CD3^＋, CD4^＋, CD8^＋ and CD25^＋ of peripheral blood were detected by flow cytometry. Results The peripheral blood CD3^＋, CD4^＋ and CD4^＋/CD8^＋ in ovarian cancer group were lower than those in control group （0.5524 ± 0.1121 vs. 0.6685 ±0.0869,0.3183 ±0.0864 vs. 0.4139 ±0.0524, 1.06 ±0.29 vs. 1.43 ±0.21 ）, CD4^＋ CD25^＋ was higher than that in control group （0.1026 ±0.0418 vs. 0.0287 ±0.0132）, there was significant difference between two groups （P 〈0.05）. There was no significant changes observed 1 week after chemotherapy （P 〉 0.05 ）. Three weeks after chemotherapy, the CD3^＋, CD4^＋ and CD4^＋/CD8^＋ in ovarian cancer group were higher and CD4^＋ CD25^＋ was lower, there were significant difference between two groups（P 〈 0.05 ）. Conclusions The ratio of lymphocyte sub-cluster is imbalance in the patients with ovarian cancer. Chemotherapy can improve the immunosuppression condition and recovery the ratio of lymphocyte sub-cluster in the patients with ovarian cancer.